跳至主要内容
临床试验/IRCT20210508051225N1
IRCT20210508051225N1招募中3 期

Comparison of the effects of Shilajit (Momiai) with placebo on clinical course, severity indices, admission duration and mortality rate in patients with moderate Coronavirus disease 2019 (COVID-19): A triple -blind randomized controlled trial

Gonabad University of Medical Sciences0 个研究点目标入组 110 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Diagnosis of moderate COVID-19 disease (based on the World Health Organization laboratory and clinical criteria)
  • Receiving standard and routine medications for moderate COVID-19 based on management protocols for COVID-19
  • age between 18 and 75 years old
  • signing the written informed consent form

排除标准

  • Immune deficiency conditions (receiving chemotherapy, organ or bone marrow transplantation, autoimmune diseases)
  • History of chronic pulmonary disease
  • Participating or being registered for other trials
  • Severe renal failure (GFR< 30ml/min)
  • Liver failure
  • Heart failure (EF<40%)
  • History underlying diseases including diabetes and hypertension

研究者

发起方
Gonabad University of Medical Sciences

相似试验